Golvatinib
- Generic Name
- Golvatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C33H37F2N7O4
- CAS Number
- 928037-13-2
- Unique Ingredient Identifier
- 516Z3YP58E
- Background
Golvatinib has been investigated for the treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01433991
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital / Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath